Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

Summary

Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain associated with chronic pancreatitis. Secondary objectives were: * to assess the safety and tolerability of REGN475/SAR164877 in patients with chronic pancreatitis pain; * to characterize the pharmacokinetic, pharmacodynamic, and immunogenicity profiles of REGN475/SAR164877 in this population; * to measure the change in the total daily dose of rescue medications required.

Timeline

Start

2009-12

Primary completion

2011-01

Completion

2011-01

Outcome

Outcome not reported

Stopped (Enrollment): “Business decision due to low subject recruitment and enrollment”

Drugs

Indications

No indication recorded.